Behind the Paper
The real stories behind the latest research papers, from conception to publication, the highs and the lows
The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective cytotoxic activity in neuroblastoma
Our recent study revealed that the chemotherapeutic CX-5461 primarily binds and inhibits TOP2B, exhibiting selective cytotoxicity in neuroblastoma cells, which overexpress TOP2B. As such, pharmacological targeting of TOP2B raises safety concerns due to off-target drug interactions with this gene.
Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150
Proton pump inhibitors (PPIs) are commonly used concomitant to cancer treatment and they induce gut microbiota changes. It’s increasingly apparent that gut dysbiosis can reduce the effectiveness of immune checkpoint inhibitors (ICI). However, little is known on PPI effects on outcomes with ICIs.
When your body attacks itself – BTK inhibition shows promise for the treatment of chronic spontaneous urticaria (an autoimmune disease)
In a recent clinical trial, patients who had chronic spontaneous urticaria (CSU) for more than 6 months that would not respond to high doses of standard treatment (H1-antihistamines) – were enrolled to evaluate a “BTK blocker” drug, called, "fenebrutinib".
Silver nanoparticle-incorporated hydrogel augments the cancer immunotherapy through modulating oral microbiome
Hydrogel-embedded silver nanoparticles and specific exogenous bacteria augment anti-tumour immune responses of oral squamous cell carcinoma by modulation of oral microbiota.
